[go: up one dir, main page]

CA2496572A1 - Compositions et procedes therapeutiques contre les cancers caracterises par l'expression de l'antigene mn/ca ix associe aux tumeurs - Google Patents

Compositions et procedes therapeutiques contre les cancers caracterises par l'expression de l'antigene mn/ca ix associe aux tumeurs Download PDF

Info

Publication number
CA2496572A1
CA2496572A1 CA002496572A CA2496572A CA2496572A1 CA 2496572 A1 CA2496572 A1 CA 2496572A1 CA 002496572 A CA002496572 A CA 002496572A CA 2496572 A CA2496572 A CA 2496572A CA 2496572 A1 CA2496572 A1 CA 2496572A1
Authority
CA
Canada
Prior art keywords
carbonic anhydrase
residues
antibody
seq
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002496572A
Other languages
English (en)
Inventor
Justin Wong
Jill Winter
Guita Lalehzadeh
Robert Warne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2496572A1 publication Critical patent/CA2496572A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne des compositions et des procédés utiles pour inhiber la prolifération de cellules prénéoplastique ou néoplastiques CA IX + chez un mammifère. Ces compositions sont des anticorps anti-CA IX et d'autres agents inhibiteurs qui ciblent l'activité d'anhydrase carbonique sur ces cellules. Ces anticorps anti-CA IX antagonistes ou fragments de liaison d'antigène de ces derniers réagissent de manière spécifique avec un épitope inhibiteur de CA IX ou un variant biologiquement actif de celui-ci. La formation d'un complexe anticorps-antigène entre les anticorps anti-CA IX antagonistes ou les fragments de liaison d'antigène de ce dernier et les épitopes inhibiteurs respectifs, entraîne l'inhibition de l'activité d'anhydrase carbonique de CA IX ou d'un variant biologiquement actif de ce dernier. L'invention porte sur d'autres agents à petites molécules qui inhibent l'activité d'anhydrase carbonique de CA IX ou d'un variant biologiquement actif de ce dernier et sur des dosages de criblage permettant d'identifier ces agents. Les anticorps anti-CA IX antagonistes, les fragments de liaison d'antigène de ce dernier, et d'autres agents inhibiteurs de CA IX susmentionnés sont utiles dans le traitement de cancers caractérisés par l'expression de l'antigène CA IX associé aux tumeurs.
CA002496572A 2002-08-23 2003-08-25 Compositions et procedes therapeutiques contre les cancers caracterises par l'expression de l'antigene mn/ca ix associe aux tumeurs Abandoned CA2496572A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US40557702P 2002-08-23 2002-08-23
US60/405,577 2002-08-23
US64693403A 2003-08-22 2003-08-22
US10/646,934 2003-08-22
PCT/US2003/026612 WO2004017923A2 (fr) 2002-08-23 2003-08-25 Compositions et procedes therapeutiques contre les cancers caracterises par l'expression de l'antigene mn/ca ix associe aux tumeurs

Publications (1)

Publication Number Publication Date
CA2496572A1 true CA2496572A1 (fr) 2004-03-04

Family

ID=31949897

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002496572A Abandoned CA2496572A1 (fr) 2002-08-23 2003-08-25 Compositions et procedes therapeutiques contre les cancers caracterises par l'expression de l'antigene mn/ca ix associe aux tumeurs

Country Status (5)

Country Link
EP (1) EP1576010A4 (fr)
JP (1) JP2005536220A (fr)
AU (1) AU2003268180A1 (fr)
CA (1) CA2496572A1 (fr)
WO (1) WO2004017923A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2477163C (fr) 2002-02-21 2010-07-27 Institute Of Virology Forme soluble d'anhydrase carbonique ix- (s-ca-ix), dosage servant a detecter la co-expression de s-ca ix et ca ix's en utilisant le her-2/neu/c-erbb-2, et des anticorps monoclonales ca ix-specifique a des epitopes non-immunodominants
US7833734B2 (en) 2002-11-26 2010-11-16 Institute Of Virology Of The Slovak Academy Of Sciences CA IX-specific inhibitors
DOP2006000277A (es) * 2005-12-12 2007-08-31 Bayer Pharmaceuticals Corp Anticuerpos anti mn y métodos para su utilización
WO2008091798A2 (fr) * 2007-01-22 2008-07-31 Xencor, Inc. Anticorps de ca9 optimises et methodes d'utilisation associees
US20110015158A1 (en) * 2007-12-11 2011-01-20 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
EP3966253A4 (fr) * 2019-05-06 2023-02-22 Navi Bio-Therapeutics, Inc. Anticorps anti-anhydrase carbonique ix

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5955075A (en) * 1992-03-11 1999-09-21 Institute Of Virology, Slovak Academy Of Sciences Method of inhibiting tumor growth using antibodies to MN protein
EP1123387B1 (fr) * 1998-10-23 2007-10-17 Institute Of Virology Gene et proteine mn

Also Published As

Publication number Publication date
WO2004017923A2 (fr) 2004-03-04
JP2005536220A (ja) 2005-12-02
WO2004017923A3 (fr) 2005-07-14
EP1576010A2 (fr) 2005-09-21
EP1576010A4 (fr) 2006-12-27
AU2003268180A8 (en) 2004-03-11
AU2003268180A1 (en) 2004-03-11

Similar Documents

Publication Publication Date Title
AU2018236755B2 (en) Anti-folate receptor alpha antibodies and uses thereof
EP2847225B1 (fr) Anticorps anti-claudin 18.2 utiles dans le diagnostic du cancer
CN107250160B (zh) 人源化cc趋化因子受体4 (ccr4)抗体及其使用方法
US20160130344A1 (en) Anti-gcc antibody molecules and methods for use of same
JP2009531031A (ja) 抗−腫瘍細胞抗原抗体療法
CN101679526A (zh) 介导癌细胞细胞毒性的人源化和嵌合抗trop-2抗体
JP2004520806A (ja) 腫瘍の診断と治療のための組成物と方法
JP2004537534A (ja) 腫瘍の診断及び治療のための組成物及び方法
CN101432422A (zh) 显示trop-2表面表达的细胞的细胞毒性介导
KR102550489B1 (ko) 암 진단에 유용한 항체
US10787516B2 (en) Antibodies that bind to AXL proteins
JP2009527507A (ja) Ｃｄ６３の表面発現を示す細胞に対する細胞傷害性介入
HK1201045A1 (en) Compositions and methods for the diagnosis and treatment of tumor
KR101789338B1 (ko) 이소형 특이적 항-ｈｅｒ４ 항체
KR20090029276A (ko) 헵신을 표적화하기 위한 방법 및 조성물
JP2004520810A (ja) 腫瘍の診断と治療のための組成物と方法
US20090252738A1 (en) Compositions and methods of therapy for cancers characterized by expression of the tumor-associated antigen mn/ca ix
US20070237772A1 (en) Tumor association of mdl-1 and methods
CA2496572A1 (fr) Compositions et procedes therapeutiques contre les cancers caracterises par l'expression de l'antigene mn/ca ix associe aux tumeurs
JP2022512644A (ja) フィラミンａに対する抗体およびその治療上の使用
US20040258696A1 (en) Compositions and methods for the diagnosis and treatment of tumor
AU2004324192A1 (en) Method for treating tumors using anti-osteopontin antibodies
JP2004520808A (ja) 腫瘍の診断と治療のための組成物と方法
HK40077698A (en) Antibodies against claudin 18.2 useful in cancer diagnosis
HK40076088A (en) Humanized cc chemokine receptor 4 (ccr4) antibodies and methods of use thereof

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead